pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 38 Non-oncology: 25
Oncology: 13
Under Consideration for Negotiation 20 Non-oncology: 8
Oncology: 12
Completed Negotiations 859 With Letter of Intent: 747
Without agreement: 112
Negotiations That Were Not Pursued 111

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Penthrox Knight Therapeutics Inc. Adult patients undergoing minor gynecological, ambulatory, or emergency procedures
Nubeqa Bayer Inc. For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Vanflyta Daiichi Sankyo Pharma Canada In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid
Myfembree Knight Therapeutics Inc. Management of heavy menstrual bleeding associated with uterine fibroids
Stivarga Bayer Inc. For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Tysabri Biogen Canada Inc. Multiple Sclerosis, Relapsing-Remitting
Mavenclad EMD Serono Canada, a division of EMD Inc. Multiple Sclerosis, Relapsing-Remitting
Wegovy Novo Nordisk Canada Inc. Weight Management

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Abilify Asimtufii Otsuka Canada Pharmaceutical Inc. Schizophrenia
Keytruda Merck Canada Inc. For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
Keytruda Merck Canada Inc. For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in
Ferinject CSL Vifor Iron deficiency in adult patients with heart failure
Ferinject CSL Vifor Iron Deficiency Anemia
Ayvakyt Medison Pharma Canada Inc. Advanced Systemic Mastocytosis
Oslya Mantra Pharma Multiple Indications
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.​
Rezurock Sanofi-Aventis Canada Inc. Chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older, after failure of at least two prior lines of systemic therapy.

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks